日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

ZuoGui Pill Ameliorates Alzheimer's Disease-Like Pathology in 3xTg-AD Mice by Targeting Aβ Production, Tau Phosphorylation, Synaptic Loss, and Neuroinflammation.

左归丸通过靶向Aβ生成、Tau磷酸化、突触丢失和神经炎症来改善3xTg-AD小鼠的阿尔茨海默病样病理。

期刊:Molecular Neurobiology
影响因子:4.3
doi:10.1007/s12035-025-05336-z
Li Song, Wang Dezhong, Li Anqi, Wang Tao, Chen Xinghai, Li Haojing, Wang Tong, Xie Yanpeng, Liang Junyi, Cai Xiaojun
神经炎症
神经科学
TAU
Immunology/Inflammation
炎症
磷酸化
发表日期：2025
文献求助 收藏

Exploring the relationship between lipid metabolism and cognition in individuals living with stable-phase Schizophrenia: a small cross-sectional study using Olink proteomics analysis

探索稳定期精神分裂症患者脂质代谢与认知之间的关系：一项采用Olink蛋白质组学分析的小型横断面研究

期刊:BMC Psychiatry
影响因子:3.6
doi:10.1186/s12888-024-06054-x
Zheng, Yingkang; Cai, Xiaojun; Wang, Dezhong; Chen, Xinghai; Wang, Tao; Xie, Yanpeng; Li, Haojing; Wang, Tong; He, Yinxiong; Li, Jiarui; Li, Juan
精神分裂症
神经科学
代谢
发表日期：2024
文献求助 收藏

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

在真实世界中，阿来替尼作为ALK阳性晚期非小细胞肺癌的一线治疗：一项中国人群的初步分析

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-22-803
Zou, Zihua; Gu, Yangchun; Liang, Li; Hao, Xuezhi; Fan, Chengjuan; Xin, Tao; Zhao, Songchen; Liu, Ziling; Guo, Ye; Ma, Kewei; Li, Haojing; Zhang, Cuiying; Shan, Li; Zhang, Yan; Dong, Guilan; Peng, Yumei; Shen, Fangfang; Song, Xia; Christopoulos, Petros; van der Wekken, Anthonie J; Okuda, Katsuhiro; Ekman, Simon; Xing, Puyuan; Li, Junling
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2022
文献求助 收藏

A non-functional 5' ALK fusion validated at the RNA level as a classical EML4-ALK that responds well to the novel ALK inhibitor ensartinib: A case report

一例经RNA水平验证为经典EML4-ALK融合基因但无功能的5' ALK融合基因，对新型ALK抑制剂恩沙替尼反应良好：病例报告

期刊:Frontiers in Medicine
影响因子:3
doi:10.3389/fmed.2022.979032
Yang, Hong; Li, Haojing; Fang, Yu; Li, Zhijun; Zhu, Jianhua; Liu, Huan; Lu, Chao; Zhang, Xiaoyan; Ma, Tonghui; Zhang, Cuiying
ALK
发表日期：2022
文献求助 收藏

Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China

中国一项多中心回顾性分析：一线克唑替尼序贯阿来替尼治疗晚期ALK阳性非小细胞肺癌的临床疗效、长期生存率及耐受性。

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.14232
Zou, Zihua; Hao, Xuezhi; Zhang, Cuiying; Li, Haojing; Dong, Guilan; Peng, Yumei; Ma, Kewei; Guo, Ye; Shan, Li; Zhang, Yan; Liang, Li; Gu, Yangchun; Xing, Puyuan; Li, Junling
肺癌
肿瘤
肿瘤免疫
ALK
细胞生物学
发表日期：2022
文献求助 收藏

Influence of schisantherin A on the pharmacokinetics of lenvatinib in rats and its potential mechanism

五味子甲素对仑伐替尼大鼠体内药代动力学的影响及其潜在机制

期刊:Journal of Gastrointestinal Oncology
影响因子:2
doi:10.21037/jgo-22-174
Yanjun Cui, Yinling Ma, Ying Li, Haojing Song, Zhanjun Dong
信号转导
发表日期：2022
文献求助 收藏